This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Segawa, N. Articles by Kakudo, K. Search for Related Content PubMed PubMed Citation Articles by Segawa, N. Articles by Kakudo, K.

Phosphorylation of Mitogen-activated Protein Kinase is Inhibited by Calcitonin in DU145 Prostate Cancer Cells¹

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, 569-8686 [N. S., Y. K.], and Second Department of Pathology, Wakayama Medical College, Wakayama City, Wakayama, 641-0012 [M. N., Y. N., I. M., K. K.], Japan

One of the causes of insensitivity to androgen ablation therapy in prostate cancer is thought to be attributable to elevated neuropeptides secreted by neuroendocrine cells in the tumor mass. Calcitonin (CT), one of these neuropeptides, is reported to be associated with the growth of prostate cancer. There is an increase in mitogen-activated protein (MAP) kinase activation as prostate cancer progresses to a more advanced and androgen-independent disease. We examined the effect of CT on signal transduction and the relation between CT and early-response genes in the human androgen-insensitive prostate cancer cell line, DU145. The basal phosphorylation level of extracellular signal-regulated kinase 1/2, which is a key kinase in the mediation of growth factor-induced mitogenesis in prostate cancer cells, was constitutively up-regulated. N-[2-(4-bromocinnamyl) aminoethyl]-5-isoquinoline-sulfonamide (H89), a specific inhibitor of protein kinase A, potentiated the effects of more increased phosphorylation of extracellular signal-regulated kinase 1/2. CT induced the inhibition of this MAP kinase phosphorylation, and this effect was completely abolished by pretreatment with H89. Our findings demonstrate that CT caused the inhibition of constitutive MAP kinase phosphorylation in a protein kinase A-dependent manner in DU145. The transient increase of c-fos expression was detected after CT treatment, whereas expression of c-jun RNA was down-regulated after CT treatment. These results suggest that CT may regulate early-response genes, c-fos and c-jun, via a MAP kinase cascade. In conclusion, these findings suggest that DU145 might be a useful model as a therapeutic approach of neuropeptides in androgen-independent prostatic carcinoma.

This article has been cited by other articles:

				Y. Zhong, H. J. Armbrecht, and S. Christakos Calcitonin, a Regulator of the 25-Hydroxyvitamin D3 1{alpha}-Hydroxylase Gene J. Biol. Chem., April 24, 2009; 284(17): 11059 - 11069. [Abstract] [Full Text] [PDF]

				M. Nakamura, B. Han, T. Nishishita, Y. Bai, and K. Kakudo Calcitonin targets extracellular signal-regulated kinase signaling pathway in human cancers J. Mol. Endocrinol., December 1, 2007; 39(6): 375 - 384. [Abstract] [Full Text] [PDF]

				S. Thomas, S. Chigurupati, M. Anbalagan, and G. Shah Calcitonin Increases Tumorigenicity of Prostate Cancer Cells: Evidence for the Role of Protein Kinase A and Urokinase-Type Plasminogen Receptor Mol. Endocrinol., August 1, 2006; 20(8): 1894 - 1911. [Abstract] [Full Text] [PDF]

				S. Chigurupati, T. Kulkarni, S. Thomas, and G. Shah Calcitonin Stimulates Multiple Stages of Angiogenesis by Directly Acting on Endothelial Cells Cancer Res., September 15, 2005; 65(18): 8519 - 8529. [Abstract] [Full Text] [PDF]

				Z Culig, H Steiner, G Bartsch, and A Hobisch Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours Endocr. Relat. Cancer, June 1, 2005; 12(2): 229 - 244. [Abstract] [Full Text] [PDF]